This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hogan, P. A.
Right arrow Articles by Sheehan, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hogan, P. A.
Right arrow Articles by Sheehan, D. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1998, p. 3313-3314, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Macrolide Susceptibility and beta -Lactamase Production among Haemophilus influenzae Isolates in the United States, 1996-1997

Patricia A. Hogan* and Daniel J. Sheehan

U.S. Pharmaceuticals Group, Pfizer Inc., New York, New York 10017

Received 23 April 1998/Returned for modification 10 August 1998/Accepted 10 September 1998

In 1996 and 1997, 68 hospital laboratories throughout the United States determined the beta -lactamase production and susceptibility to macrolides of 1,998 isolates of Haemophilus influenzae obtained from patients with community-acquired respiratory tract infections. The MICs at which 90% of the isolates are inhibited of azithromycin, erythromycin, and clarithromycin were 4, 8, and 16 µg/ml, respectively. By National Committee for Clinical Laboratory Standards interpretive criteria, 99 and 78% of the isolates were susceptible to azithromycin and clarithromycin, respectively. The prevalence of beta -lactamase production was 32%.

* Corresponding author. Mailing address: U.S. Pharmaceuticals Group, Pfizer Inc., New York, NY 10017. Phone: (212) 573-3923. Fax: (212) 573-5916. E-mail: hoganp{at}pfizer.com.

Antimicrobial Agents and Chemotherapy, December 1998, p. 3313-3314, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Fuchs, P. C., Barry, A. L., Brown, S. D. (2001). Influence of Variations in Test Methods on Susceptibility of Haemophilus influenzae to Ampicillin, Azithromycin, Clarithromycin, and Telithromycin. J. Clin. Microbiol. 39: 43-46 [Abstract] [Full Text]  
  • Thornsberry, C., Jones, M. E., Hickey, M. L., Mauriz, Y., Kahn, J., Sahm, D. F. (1999). Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother 44: 749-759 [Abstract] [Full Text]  
  • Thornsberry, C., Ogilvie, P. T., Holley, H. P. Jr., Sahm, D. F. (1999). Survey of Susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Isolates to 26 Antimicrobial Agents: a Prospective U.S. Study. Antimicrob. Agents Chemother. 43: 2612-2623 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»